Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), announced on Tuesday developments in cannabis science from Aurora's research and genetics facility, Aurora Coast."As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Lana Culley, vice president of science and innovation at Aurora. "We strive to continuously raise the bar on product superiority and overall user experience so that we can deliver on our mission of providing patients with access to the very best medical cannabis."
Cannabis company Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) is launching the award-winning California-grown Claybourne brand in Canada, via an exclusive licensing agreement. Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) revealed its latest lineup of innovations from Greybeard, San Rafael '71 and Tasty's brands for Canadian consumers.Cannabis producer and retailer The Cannabist Company (Cboe CA: CBST) (OTCQX: CBSTF) (FSE: 3LP) announced on Wednesday the launch of its partnership with Veda Warrior, a New Jersey-based minority woman-owned Ayurvedic wellness brand.
Aurora Cannabis together with MedReleaf Australia, announced on Wednesday an enhanced product range of premium medical cannabis oil in Australia. The Canadian medical cannabis giant said the new cannabis oils include a variety of cannabinoid ratios to suit diverse patient needs and are now available for physicians to prescribe.The new products allow doctors to tailor treatments more precisely.
The U.S. Hemp Roundtable made headlines in early September as its board of directors welcomed two distinguished leaders from the hemp beverage sector to its officer ranks. New York's chief equity officer at the state Office of Cannabis Management, Damian Fagon, has formally resigned, effective November 27.
Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced on Wednesday a research grant provided to the University of British Columbia (UBC) by Genome British Columbia. he project, Genomics-enabled Aroma Breeding in Cannabis, is led by Drs. Jose Celedon, principal scientist of breeding and genetics at Aurora and Joerg Bohlmann, a professor at UBC. It focuses on validating genetic and chemical markers for fruity aroma in cannabis.
Canadian medical cannabis giant Aurora Cannabis announces on Friday the appointment of CEO Miguel Martin to the additional role of executive chairman and outgoing chairman Ron Funk as lead independent director.
Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, announced on Monday the launch of the newly developed Luo CBD lozenge. The product was developed by Vectura Fertin Pharma, and represents the company's first medical cannabis CBD lozenge to be introduced in Canada.The move follows the announced commercial collaboration between Vectura Fertin Pharma's subsidiary Cogent International and the Edmonton, Alberta-based company to leverage Aurora's Canadian medical cannabis patient platform.
In late July, nearly three months after New York Governor Kathy Hochul fired Chris Alexander, the former head of the state's Office of Cannabis Management (OCM), following an internal review, a series of high-level departures made headlines.Connecticut Social Equity Council (SEC), which manages social equity activity for the state's recreational marijuana market, got a new executive director earlier this month. Brandon McGee, who previously worked on Gov. Ned Lamont's reelection in 2022, replaced Ginne-Rae Clay, reported Marijuana Business Daily citing CT Insider.Canopy Growth Corporation and Curaleaf Holdings, Inc. announced CEO shake-ups.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has scheduled a conference call to discuss the results for its first quarter 2025 on Wednesday, August 7, 2024 at 8:00 am Eastern Time. The Canadian medical cannabis giant said it will report its financial results for the first quarter of 2025 before the opening of markets that same day. CEO Miguel Martin and CFO Simona King will host the conference call and question and answer period. Aurora made headlines last week as it was granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). The permits granted the company continued domestic cultivation, which has been underway for two years.
Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). The company said on Thursday the license grants it continued domestic cultivation, which has been underway for two years now.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced on Thursday its financial and operational results for the fourth quarter and fiscal year 2024.The company reported a 5% year-over-year increase in revenue to CA$67.4 million ($49.1 million) in the fourth quarter. Global medical cannabis net revenue grew by 20% over the same period to CA$45.6 million. The increase in net revenue1 of $7.7 million was primarily due to higher sales to Australia and Europe in the current period following the success of newly launched innovative cultivars in these markets.
Slightly over a year following Gov. Dan McKee's decision to appoint three experts to the Cannabis Control Commission with a task to regulate, license and control the medical and recreational cannabis markets in Rhode Island, the agency is about to get a leader. One of Oklahoma's top cannabis regulators Michelle Reddish is nominated by Gov. McKee to become Rhode Island's first cannabis administrator, reported Oklahoma Voice.In the meantime, nearly a dozen either cannabis companies or businesses related to the plant saw board changes recently.
Flora Growth Corp. has entered into a definitive agreement to acquire all of the issued and outstanding shares of Hamburg, Germany-based TruHC Pharma GmbH. The company's latest move to further cement its global footprint comes on the heels of a new German cannabis law that went into effect on April 1, which partially legalized cannabis. The new law allows adults over 18 in Germany to legally possess up to 25 grams of dried cannabis and cultivate up to three marijuana plants at home.As previously announced, Flora agreed to purchase TruHC Pharma GmbH in an all-stock deal in exchange for 2,770,562 of its common shares, valued at $6.4 million.
Aurora Cannabis said on Wednesday that it has obtained Good Manufacturing Practice (GMP) certification from Australia's Therapeutic Goods Administration (TGA) for its Canadian production facilities, River and Ridge. The TGA is in charge of regulating the supply, import, export, manufacturing and advertising of therapeutic goods in Australia. Obtaining TGA's GMP certification allows the Canadian cannabis giant to deliver cannabis products to Australia. The license grants approval for Aurora to broaden its product range offerings in the country, comprising dried flower, resin cartridges, pastilles and oils.
Aurora Cannabis has repaid its convertible senior notes, marking a significant milestone as it nears financial recovery. With remaining debt related to Bevo Farms Ltd, CEO Miguel Martin highlighted the company's focus on balance sheet strength, having paid off a substantial amount in convertible debt. The company posted record earnings in the third quarter, attributing success to international expansion and strategic partnerships, such as the recent collaboration with Script Assist in the UK. Analysts have identified Aurora as well-positioned to benefit from the legalization wave in Germany, given its strong export ties to the country. With a focus on medical cannabis quality and patient care, Aurora aims for positive free cash flow by year-end, showcasing a commitment to financial discipline and growth in the global cannabis market.
Aurora Cannabis has partnered with Script Assist, a UK medical cannabis prescription platform. The collaboration will offer a range of Aurora's medical cannabis products in the UK, including three new cannabis flower products launching in March. These products aim to provide UK patients with high-quality options, such as those with high THC content or balanced THC/CBD ratios. The partnership will also introduce 'Find a Doctor' on the platform to connect patients with specialized prescribing doctors. Trisha Cassidy, a managing director at Aurora UK and Ireland, highlighted the importance of improving access to medical cannabis products and providing valuable information to support patients. Overall, the partnership between Aurora and Script Assist aims to enhance the UK medical cannabis landscape and assist patients on their medical cannabis journey.
Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as The Hempshire Group's new CEO. Los Angeles-based STIIIZY INC. named Isaac Kim its new CFO earlier this month. Another California-based cannabis operator Lowell Farms appointed Jamie Schniedwind as its new director of finance. The Colorado-based medical cannabis pioneer Charlotte's Web Holdings tapped Matthew E. McCarthy, the former CEO of Ben & Jerry's Homemade, to serve on its board earlier this month. Aurora Cannabis has named Simona King, a former executive of Bristol Myers-Squibb, its new CFO.
Canadian medical cannabis company Aurora Cannabis reported its financial and operational results for Q3 2024. Net revenue increased to CAD64.4m ($42m), up from CAD61.1m in the same quarter the previous year. Medical cannabis net revenue rose by 16% to CAD45.1m, representing 70% of Aurora's consolidated net revenue. Gross profit reached CAD19.8m, up from CAD3.7m in Q3 2022, with adjusted gross profit before fair value adjustments increasing to CAD32.4m from CAD28m. The company recorded a CAD25.5m net loss compared to CAD67.2m in the same quarter in the previous year. Adjusted EBITDA came in at CAD4.3m, up from CAD3m. Miguel Martin, CEO of Aurora, said the company's international medical net revenue had seen year-on-year growth of 41%.
